Yung-Jue Bang
方荣周
MD, PhD
Professor Emeritus, Department of Internal Medicine内科荣誉教授
👥Biography 个人简介
Pioneering Korean oncologist who led the landmark ToGA trial establishing trastuzumab for HER2+ gastric cancer. Principal investigator of KEYNOTE-059 validating pembrolizumab in gastric cancer. Globally influential in defining molecular subtypes and biomarker-guided treatment for gastric cancer in Asia and worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
HER2-Targeted Gastric Cancer Treatment
Led the ToGA trial demonstrating trastuzumab plus chemotherapy improves OS in HER2+ advanced gastric cancer, creating the first targeted therapy standard in this disease.
Pembrolizumab in Gastric Cancer
Principal investigator of KEYNOTE-059, establishing pembrolizumab activity in pretreated PD-L1+ gastric cancer and guiding subsequent immunotherapy approvals.
Representative Works 代表性著作
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)
The Lancet (2010)
Landmark trial establishing the first targeted therapy standard for HER2+ advanced gastric cancer.
Pembrolizumab (MK-3475) versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061)
The Lancet (2018)
Evaluated pembrolizumab vs. paclitaxel as second-line therapy in gastric cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 方荣周 的研究动态
Follow Yung-Jue Bang's research updates
留下邮箱，当我们发布与 Yung-Jue Bang（Seoul National University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment